Skip to content

San Carlos, CA, January 25, 2021 – FlemingMartin is pleased to announce that Natera (NASDAQ: NTRA), a global pioneer in noninvasive blood-based DNA testing, has hired Stephen Willingham as Head of Translational Medicine for Oncology.

Overseeing a team of senior scientists at Natera, Stephen will define and explore biological, scientific, and clinical questions to advance patient care in oncology. Furthermore, he will collaborate closely with stakeholders spanning from “bench-to-bedside” as Natera continues to transform the management of disease worldwide.

Stephen comes to Natera after more than six years with Corvus Pharmaceuticals (NASDAQ: CRVS), where he was a founding member of the Company.  At Corvus, Stephen served as the Director of Translational Medicine and managed preclinical, translational, and biomarker development while targeting the most difficult-to-treat cancers. Prior to joining Corvus, Stephen spent six-and-a-half years as a Postdoc Research Scientist and Instructor at Stanford University School of Medicine, working under Dr. Irving Weissman.

Stephen received his Ph.D. in Genetics and Molecular Biology from the University of North Carolina and he earned his B.S. in Microbiology and Immunology at the University of Washington.

Natera LogoNatera is a worldwide genetic testing and diagnostics company that’s changing how doctors and patients manage genetic disease. Natera’s Signatera technology is the first and only circulating tumor DNA (ctDNA) surveillance tool that detects molecular residual disease (MRD) for greater clinical confidence when assessing disease recurrence or treatment response in solid tumors. To learn more, visit

Fleming Martin Color Logo Large 72 Ppi

FlemingMartin is a leading retained executive search firm with offices in Northern and Southern California. FlemingMartin partners with Boards, Private Equity Firms, and CEOs of companies to build successful execution-focused management teams. The Firm’s principals are trusted advisors and business partners who enable companies to gain powerful, far-reaching, and lasting contributions from their executive-level human capital.